Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 436 results for "lupin"

Lupin targets to acquire domestic firms this time
Millennium Post

Lupin explores opportunities for organic and inorganic growth

Earlier Exchange has sought clarification from Lupin Ltd with respect to news article appearing in Economic Times on December 15, 2014 titled "Scouting for Acquisitions" Lupin Ltd clarified that the Company actively explores opportunities for organic and ... India Infoline, 21 hours ago
Scouting for domestic buy: Lupin The Echo Of India, 4 days ago

148 images for lupin

NDTV Profit, 1 day ago, 1 day ago
Business Standard, 3 days ago
Money Today, 1 week ago
India TV, 1 week ago
Knox Village Soup, 8 hours ago
Knox Village Soup, 6 hours ago
Knox Village Soup, 1 day ago
Waldo County Village Soup, 1 day ago
Reuters, 6 days ago

Lupin gains 1%, US arm launches generic for arthritis drug

The pharma major said its US subsidiary, Lupin Pharmaceuticals Inc has launched the authorised generic for GD Searle LLC’s (a subsidiary of Pfizer Inc.) Celebrex capsules 50 mg, 100 mg, 200 mg and 400 mg strengths.
 Money Control1 week ago Lupin gains after US subsidiary launches generic for Celebrex  Business Standard1 week ago Lupin rises as its US subsidiary launches Authorized Generic for Celebrex Capsules  Arihant Capital1 week ago
Business Standard

Lupin - Pharma major innovates with technology

Innovation is everything in the fast moving Pharmaceuticals sector. And LupinLimited represents one of the most exciting pharmaceutical growth stories in India
 Money Control1 week ago Lupin launches Authorized Generic for Celebrex Capsules  India Infoline1 week ago Lupin Launches Authorized Genericfor Celebrex® Capsules  Morningstar.com1 week ago Lupin Ltd. (LUPN.BO) Launches Authorized Genericfor Celebrex Capsules 12/11/2014  ClinicSpace1 week ago

Food Allergy Laws Enforced in Britain Restaurants

Food outlets must inform public about 14 allergens ranging from nuts and milk to mustard and lupin seeds, often used in flour. Rules aimed at ending the "Russian roulette" food-allergy sufferers face when eating in restaurants, take-aways, schools ...
 NDTV6 days ago European restaurants will have to warn their customers about allergic components in the menu  News.am2 days ago New UK food allergen labelling rules for UK restaurants  Australian Food News3 days ago Hot Food Outlets Forced To List Allergens  Sky News5 days ago
Business Standard

Lupin: New product launches to drive earnings' upgrades

g sessions on launch of the anti-inflammatory Celebrex drug in the US. Lupin is one of the four generic players in the US for the drug, which has annual sales of $2.5 billion. Analysts at Motilal Oswal Securities (MOSL) expect the company to gain a market ...
 Business Standard6 days ago

Lupin gains on launch of generic for Celebrex

The stock is now trading with a gain of 1.4 per cent. Lupin is trading on a positive note for the second straight day after its US subsidiary launched generic for Celebrex capsules. Yesterday, the Pharma major, Lupin informed the BSE that the US subsidiary of ...
 India Infoline6 days ago Lupin shares gain on launch of generic form of Celebrex  Financial Express1 week ago Lupin down over 2% ahead of results  India Infoline1 month ago

RIL among Barclays' top 133 stock picks for 2015

Other Indian firms in the list include HDFC Bank, homegrown pharma major Lupin and Voltas. In its report 'Global Top Picks', Barclays expects the current bull market in global equities to continue, generating a total return of 9 per cent in 2015. RIL was the ...
 Business Standard1 week ago RIL, TCS among Barclays' top stock picks for 2015  Business Today India1 week ago Reliance Industries, TCS and Bharti Airtel among Barclays' top 133 stock picks for 2015  Economic Times1 week ago Six Indian Companies In Barclays Top 133 Stocks For 2015  The CFO Institute1 week ago

Rouble fall: Indian pharma stock slips

Shares of Lupin is down 3%, while Cipla stock is also lower 35 at Rs607.
 India Infoline1 day ago Lupin allots equity shares  Business Standard4 weeks ago
Business Standard

Pharma shares under pressure; CNX Pharma index down nearly 4%

Wockhardt, Glenmark, Torrent Pharma,Aurobindo Pharma, Lupin, Strides Arcolab and Biocon were down 5-9%. SI Reporter | Mumbai December 17, 2014 Last Updated at 10:25 IST Shares of pharmaceutical companies are under pressure, falling by up to 9% on the National ...
 Business Standard1 day ago Lupin : Patent Issued for Stable Pharmaceutical Compositions of Carvedilol  4 Traders3 weeks ago Pharma companies may post healthy numbers on strong global business, rupee fall  DNA1 month ago Here's why pharma sector will continue outperforming  Money Control2 months ago

Novartis sues Cipla over respiratory drug Onbrez

Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price. Cipla, India's fourth-largest drugmaker by revenue, launched its copy of Onbrez in New Delhi in October, citing urgent unmet need for the drug in India. "There is an ample supply of Onbrez, and ...
 Rediff.com1 day ago Novartis sues Cipla over drug patent, HC reserves verdict  Business Today India1 day ago Novartis sues India's Cipla over respiratory drug Onbrez  CNBC1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - lupin
Get updated on latest news & your favorite topics right in your inbox!
More     Less